Vertex Pharmaceuticals Inc (VRTX)
494.61
+4.61
(+0.94%)
USD |
NASDAQ |
Nov 13, 16:00
496.50
+1.89
(+0.38%)
After-Hours: 20:00
Vertex Pharmaceuticals Research and Development Expense (Quarterly): 875.90M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 875.90M |
| June 30, 2024 | 966.60M |
| March 31, 2024 | 789.10M |
| December 31, 2023 | 824.60M |
| September 30, 2023 | 810.00M |
| June 30, 2023 | 785.70M |
| March 31, 2023 | 742.60M |
| December 31, 2022 | 694.10M |
| September 30, 2022 | 645.00M |
| June 30, 2022 | 600.10M |
| March 31, 2022 | 601.10M |
| December 31, 2021 | 567.80M |
| September 30, 2021 | 467.00M |
| June 30, 2021 | 448.70M |
| March 31, 2021 | 456.00M |
| December 31, 2020 | 466.55M |
| September 30, 2020 | 493.50M |
| June 30, 2020 | 420.93M |
| March 31, 2020 | 448.53M |
| December 31, 2019 | 479.97M |
| September 30, 2019 | 555.95M |
| June 30, 2019 | 379.09M |
| March 31, 2019 | 339.49M |
| December 31, 2018 | 437.88M |
| September 30, 2018 | 330.51M |
| Date | Value |
|---|---|
| June 30, 2018 | 337.53M |
| March 31, 2018 | 310.55M |
| December 31, 2017 | 306.66M |
| September 30, 2017 | 454.95M |
| June 30, 2017 | 289.45M |
| March 31, 2017 | 273.56M |
| December 31, 2016 | 248.45M |
| September 30, 2016 | 272.37M |
| June 30, 2016 | 271.01M |
| March 31, 2016 | 255.86M |
| December 31, 2015 | 310.18M |
| September 30, 2015 | 246.28M |
| June 30, 2015 | 223.86M |
| March 31, 2015 | 215.60M |
| December 31, 2014 | 201.46M |
| September 30, 2014 | 190.94M |
| June 30, 2014 | 224.49M |
| March 31, 2014 | 238.62M |
| December 31, 2013 | 238.46M |
| September 30, 2013 | 219.44M |
| June 30, 2013 | 222.46M |
| March 31, 2013 | 218.10M |
| December 31, 2012 | 172.83M |
| September 30, 2012 | 200.16M |
| June 30, 2012 | 196.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
420.93M
Minimum
Jun 2020
966.60M
Maximum
Jun 2024
629.19M
Average
600.60M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| Gilead Sciences Inc | 1.395B |
| Bristol-Myers Squibb Co | 2.374B |
| Moderna Inc | 1.137B |
| Sarepta Therapeutics Inc | 224.48M |